Evidence map›Paper›PMID 20922044›Full record

ArticleThe open cardiovascular medicine journal2010

Cell membrane modification for rapid display of bi-functional peptides: a novel approach to reduce complement activation.

Ledia Goga, Gustavo Perez-Abadia, Sathnur B Pushpakumar, Daniel Cramer, Jun Yan, Nathan Todnem, Gary Anderson, Chirag Soni, John Barker, Claudio Maldonado

Open access · hybridAbstract read
In one paragraph

Article in The open cardiovascular medicine journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ledia GogaDepartment of Physiology and Biophysics.
Gustavo Perez-Abadia
Sathnur B Pushpakumar
Daniel Cramer
Jun Yan
Nathan Todnem
Gary Anderson
Chirag Soni
John Barker
Claudio Maldonado
University of Louisville · US

Funding

New anti-complement therapy to reduce reperfusion injuryR41HL079855 · NHLBI · ENDOPROTECH, INC. · PI MALDONADO, CLAUDIO · 2005 to 2005
$123k
NHLBI NIH HHS R41 HL079855
6 · The paper itself

Abstract

Ischemia and reperfusion of organs is an unavoidable consequence of transplantation. Inflammatory events associated with reperfusion injury are in part attributed to excessive complement activation. Systemic administration of complement inhibitors reduces reperfusion injury but leaves patients vulnerable to infection. Here, we report a novel therapeutic strategy that decorates cells with an anti-complement peptide. An analog of the C3 convertase inhibitor Compstatin (C) was synthesized with a hexahistidine (His(6)) tag to create C-His(6). To decorate cell membranes with C-His(6), fusogenic lipid vesicles (FLVs) were used to incorporate lipids with nickel (Ni(2+)) tethers into cell membranes, and these could then couple with C-His(6). Ni(2+) tether levels to display C-His(6) were modulated by changing FLV formulation, FLV incubation time and FLV levels. SKOV-3 cells decorated with C-His(6) effectively reduced complement deposition in a classical complement activation assay. We conclude that our therapeutic approach appears promising for local ex vivo treatment of transplanted organs to reduce complement-mediated reperfusion injury.

Indexed as

Cell membrane.ComplementComplement inhibitorsCompstatinDrug deliveryIschemiaLiposomesReperfusion

Identifiers

PMID20922044
PMCPMC2948132
OpenAlexW1897296214

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.